Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

mine bitartrate are fully-compliant due to the drug's strict every-six hour dosing schedule and dose-limiting side effects, including gastrointestinal ("GI") problems such as stomach aches, nausea and vomiting.

Patrice Rioux, M.D., Ph.D., Raptor's Chief Medical Officer stated, "We are pleased that enrollment is now underway in our Phase 2b clinical trial in cystinosis. This is an underserved patient population and there is a compelling need for an improved treatment option. Many patients are unable to take adequate levels of the drug to halt the progression of their disease, which gradually destroys the organs in the body. We believe DR Cysteamine could have positive effects on the long-term health of cystinosis patients as well as the quality of life for patients, their families and caregivers."

Bruce Barshop, M.D., Ph.D., Professor of Clinical Pediatrics at UCSD and principal investigator for the cystinosis clinical trial, commented, "The initiation of this cystinosis trial offers us an opportunity to evaluate the potential for an improved treatment invented here at UCSD and further developed by Raptor. We're pleased to collaborate with Raptor in this effort to advance the standard of care in cystinosis."

About DR Cysteamine

DR Cysteamine is an enteric-coated micro-bead formulation of cysteamine bitartrate. Raptor obtained an exclusive, worldwide license to DR Cysteamine, as well as orphan drug designation from the FDA for DR Cysteamine for the treatment of nephropathic cystinosis, through its December 2007 acquisition of Encode Pharmaceuticals. In March 2008, Raptor acquired an exclusive worldwide license to intellectual property from the University of California, San Diego for use of cysteamine and DR Cysteamine for the treatment of non-alcoholic steatohepatitis ("NASH"), a progressive liver disease believed to affect 2-5% of the U.S. population. In October, 2008 Raptor ann
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 18, 2014 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD), a ... and products for advanced microarray diagnostics, today announced it ... 22 at 2:00 pm ET.  During ... a brief review of SQI,s recent commercialization progress and ... industry veteran recently appointed to the Board of Directors ...
(Date:8/18/2014)... WASHINGTON , Aug. 18, 2014   Sterne, ... law firm in Washington, DC , ... Inter Partes Review (IPR) with the U.S. ... Inc., a subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI). ... co-owned, or licensed by Myriad Genetics, Inc. These patents ...
(Date:8/18/2014)... HIV Infection Drug Market and Pipeline Insight is a ... infection and the number of deaths due to AIDS has ... the globe. It has been estimated that the death rate ... with the rates for children being even much lower. A ... has been the improved access to antiretroviral drugs and therapy ...
(Date:8/18/2014)... 2014 According to the ... Application (Municipal Wastewater Treatment and Industrial Wastewater Treatment), ... Tubular), By Configuration (Internal/Submerged and External/Sidestream), and By ... The market for membrane bioreactor systems is projected ... a CAGR of 15.28% between 2014 and 2019. ...
Breaking Biology Technology:SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 2SQI Diagnostics Announces Investor Conference Call with Dr. Allan Pronovost 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... SAN DIEGO, Nov. 4 ADVENTRX Pharmaceuticals,Inc. (Amex: ... President,Operations of ADVENTRX, is scheduled to present at the ... is scheduled to present,on Tuesday, November 11th, 2008 at ... takes place November 10-12, 2008 at the,Palace Hotel in ...
... patients, in only 75 minutes using Cepheid,s ... Dorset County Hospital (DCH) is,working hard to reduce ... enhanced MRSA surveillance. As part of the programme, DCH ... hospitals to identify patients who carry the bacteria on ...
... DURECT Corporation,(Nasdaq: DRRX ) announced today financial results ... were $6.6 million for the three months,ended September 30, ... in,2007. Net loss for the three months ended September ... of $7.9 million for the same period in,2007., ...
Cached Biology Technology:Dorset County Hospital Enhances MRSA Surveillance Programme Through Rapid Patient Screening 2Dorset County Hospital Enhances MRSA Surveillance Programme Through Rapid Patient Screening 3DURECT Corporation Announces Third Quarter 2008 Financial Results 2DURECT Corporation Announces Third Quarter 2008 Financial Results 3DURECT Corporation Announces Third Quarter 2008 Financial Results 4DURECT Corporation Announces Third Quarter 2008 Financial Results 5DURECT Corporation Announces Third Quarter 2008 Financial Results 6DURECT Corporation Announces Third Quarter 2008 Financial Results 7DURECT Corporation Announces Third Quarter 2008 Financial Results 8
(Date:8/18/2014)... mass is made up of rangelands, which include grasslands ... alarming rate. Woody plants, such as trees and shrubs, ... loss of critical habitat and causing a drastic change ... specifically meat. , Researchers with Arizona State University,s ... this loss in both the United States and Argentina. ...
(Date:8/18/2014)... Denmark, and the University of Wisconsin-Madison, USA, have developed a ... both climate and land use change. This new metric was ... of combined rates of climate and land use for the ... have just been published in Nature Climate Change , ... biodiversity and ecosystem function due to the individual or combined ...
(Date:8/18/2014)... with the pygmy phenotype is probably a selective ... team of researchers, but all African pygmy phenotypes ... a more recent adaptation than previously thought., "I,m ... their very challenging environments," said George H. Perry, ... "Tropical rainforests are difficult for humans to live ...
Breaking Biology News(10 mins):Trees and shrubs invading critical grasslands, diminish cattle production 2Trees and shrubs invading critical grasslands, diminish cattle production 3The double threat of climate and land use change enhances risks to biodiversity 2Pygmy phenotype developed many times, adaptive to rainforest 2
... flowers have shifted away from using insects as pollinators and ... birds. In a study published in New Phytologist ... for the first time that Australian native flowers exclusively pollinated ... discriminated by those birds. Dr Adrian Dyer of Monash ...
... Institutet in Sweden have found an explanation for why ... the brains of people with schizophrenia or bipolar disease ... scientific periodical Molecular Psychiatry , identifies a gene ... discovery contributes to the further understanding of the link ...
... of birds, schools of fish, and groups of any other ... aquatic microorganisms, Andrea Giometto, a researcher EPFL and Eawag, showed ... according to the same mathematical expression, where the only unknown ... His article was published in in PNAS in ...
Cached Biology News:For birds, red means 'go' 2New gene variant may explain psychotic features in bipolar disorder 2One law to rule them all -- sizes within a species appear to follow a universal distribution 2
... Early Drug Development with Imaging Mass Spectrometry ... compound localization data in early drug development ... spectrometry service maps unlabeled ions ... you can localize drugs and metabolites prior ...
... The AccuSpot automates LC micro-fractionation, ... With the AccuSpot system, LC eluent ... onto target plates, in trace amounts. ... target plates for MALDI-TOF-MS measurements. When ...
... The JNK (c-Jun NH2-terminal kinase) ... three identified MAP kinase pathways in ... response to environmental stress, is associated ... itself, and is implicated in the ...
... knockdown of all human, mouse, and ... Genomewide, predesigned siRNAs for a ... , Ready-to-use, convenient matching solutions for ... Cost-effective RNAi and downstream analysis ...
Biology Products: